IBS Issues

IBS - A Daily Challenge

Irritable Bowel Syndrome (IBS) is one of the most widespread and costly gastrointestinal disorders. Globally, the prevalence of IBS is estimated to be around 15%, with symptoms occurring in about 10-20% of the population in Western countries. The condition is characterized by symptoms such as abdominal pain, bloating, and irregular bowel movement. These symptoms can lead to a significant deterioration in the quality of life for affected individuals.

Alnozine, developed by Milmed Unico AB, is classified as a dietary supplement and adheres to the regulations set by the National Food Agency. This unique pharmabiotic product is derived from yeast cells treated with electromagnetic millimeter waves. It is designed to be part of a balanced diet and contribute to a less troubled stomach.

Alnozine (Milmed) är patentskyddat, patentnr PCT/SE2022/050656  ”YEAST FOR THE TREATMENT OF INFLAMMATION”. Grund för patentet är två studier studier som bägge är publicerade vetenskapliga artiklar, se OM ALNOZINE.

The photo of internal organs is on the women's body against gray background, Concepts of health problems

Customer stories

alnozine-forest-product-placement-NEW

Clinical Studies and Research

Alnozine™ är ett kosttillskott som har genomgått forskning och samarbeten med ledande forskningsinstitutioner, till exempel med Sapienza University. Dessa studier har genomförts för att förstå mer om Alnozines effekt och verkningsgrad samt att det inte finns någon toxicitet i produkten. Det är viktigt att notera att Alnozine är avsett att användas som ett komplement till en balanserad kost.

alnozine-forest-product-placement-NEW

Try Alnozine today

Shopping Basket